Baudax Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Baudax Bio, a pharmaceutical company focused on acute care products, announced that Gerri Henwood, the President and CEO, will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Baudax Bio, a pharmaceutical company focused on acute care products, announced that Gerri Henwood, the President and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The corporate presentation will be available for on-demand listening starting September 13 at 7:00 a.m. ET, accessible on the company's website. Baudax Bio's key product, ANJESO, is a 24-hour intravenous COX-2 preferential NSAID for managing moderate to severe pain. The company also has a pipeline of innovative pharmaceutical assets.
Details
News Market Reaction – BXRX
The recorded move for BXRX in the trading session of this news was +0.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021.
The presentation will be made available for on-demand listening beginning Monday, September 13, 2021 at 7:00 a.m. Eastern Time and may be accessed on the “Presentations” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. The recording will be made available for a period of 30 days following the event.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused on commercializing and developing innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs. For more information, please visit www.baudaxbio.com.
CONTACTS:
Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
baudaxbio@argotpartners.com
Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.